Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

M. S. Czuczman1* J. P. Leonard2 S. Jung3 J. L. Johnson3 E. D. Hsi4 J. C. Byrd5 and B. D. Cheson6

首页> 外文期刊>Annals of Oncology >Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

【24h】

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of Oncology》 |2012年第9期|p.2356-2362|共7页
作者
M. S. Czuczman1* J. P. Leonard2 S. Jung3 J. L. Johnson3 E. D. Hsi4 J. C. Byrd5 and B. D. Cheson6;
展开▼
作者单位

1Roswell Park Cancer Institute, Buffalo 2Weill Medical College of Cornell University, New York 3CALGB Statistical Office, Duke University Medical Center, Durham 4Cleveland Clinic Foundation, Cleveland 5The Ohio State University, Columbus 6Lombardi Cancer Center, Georgetown University Hospital, Washington, USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (vol 23, pg 2356, 2012) [J] . Czuczman M. S., Leonard J. P., Jung S., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第11期

机译：Galiximab的II期试验（抗CD80单克隆抗体）加里妥昔单抗（CalgB 50402）：卵泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性（第23卷，PG 2356,2012）
2. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular lymphoma international prognostic index (FLIPI) score is predictive of upfront immunotherapy responsiveness [J] . CzuczmanM.S., LeonardJ.P., JungS., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第9期

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期试验：滤泡性淋巴瘤国际预后指数（FLIPI）得分可预测前期免疫疗法的反应性
3. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. [J] . Leonard JP, Friedberg JW, Younes A, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第7期

机译：galiximab（抗CD80单克隆抗体）与利妥昔单抗联合用于复发或难治性滤泡性淋巴瘤的I / II期研究。
4. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness [O] . M S Czuczman, J P Leonard, S Jung, -1

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期临床试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性
5. Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness” [O] . M.S. Czuczman, J.P. Leonard, S. Jung, 2018

机译：矫正“Galiximab的第二阶段试验”（抗CD80单克隆抗体）加里妥昔单抗（CalgB 50402）：卵泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性“

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

著录项

相似文献

相关主题

期刊订阅